Olaparib: Transcending mutational barriers

Olaparib: Transcending mutational barriers

Bibliographic Details
Main Author:	Abhishek Chandna
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2019-01-01
Series:	Indian Journal of Urology
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2019;volume=35;issue=1;spage=85;epage=86;aulast=Chandna

Similar Items

Lynparza (olaparib)
by: Erik Škof, et al.
Published: (2016-06-01)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
by: Hong Yang, et al.
Published: (2020-11-01)

Olaparib in the management of ovarian cancer
by: Bixel K, et al.
Published: (2015-08-01)

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation
by: Xue-Song Zhao, et al.
Published: (2019-12-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
by: Li X, et al.
Published: (2021-04-01)

The combination of olaparib and camptothecin for effective radiosensitization
by: Miura Katsutoshi, et al.
Published: (2012-04-01)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
by: Cheng Y, et al.
Published: (2018-09-01)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021-04-01)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic mutation
by: Lee S. Schwartzberg, et al.
Published: (2021-04-01)

Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase DM, et al.
Published: (2016-04-01)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
by: Rachel Dunn, et al.
Published: (2021-01-01)

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene
by: Azam Ghafoor, MD, et al.
Published: (2021-10-01)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
by: Yi Ma, et al.
Published: (2018-10-01)

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
by: Wu M, et al.
Published: (2018-12-01)

Sensitization of Cancer Cells to Chemotherapy or Olaparib by ILK Inhibition
by: Kuo, Yi-Chiu
Published: (2016)

The anticancer activity of olaparib in small cell lung cancer
by: Chang, Ying-Feng, et al.
Published: (2016)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
by: Jean-David Fumet, et al.
Published: (2020-08-01)

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
by: S. Mazzucchelli, et al.
Published: (2017-08-01)

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
by: Fatima Karzai, et al.
Published: (2018-12-01)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
by: Brian T. Burgess, et al.
Published: (2020-02-01)

The Open Translation MOOC: creating online communities to transcend linguistic barriers
by: Tita Beaven, et al.
Published: (2013-08-01)

An educational formula : critical border education that transcends social and linguistic barriers
by: Villarreal, Elizabeth
Published: (2012)

Transcendence
by: Hannan, Holis
Published: (2011)

Transcendence
by: Klinke, James
Published: (2012)

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer
by: Wang Z, et al.
Published: (2021-08-01)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
by: Ana Beatriz Varanda, et al.
Published: (2020-07-01)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
by: Montemorano L, et al.
Published: (2019-12-01)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
by: De Felice F, et al.
Published: (2017-03-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

Transcendence of Prejudice or Transcendence With Prejudice? Stronger Beliefs Regarding Transcendence are Correlated with Greater Intergroup Bias
Published: (2013)

Transcendent experience or the transcendence of experience? An analysis of transcendent realization in Shankara, Ibn Arabi and Meister Eckhart
by: Shah-Kazemi, Reza
Published: (1994)

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
by: Ben Fulton, et al.
Published: (2018-01-01)

Discussion on the Barrier and Transcend of Language from Case Studies of Deaf’s Life Experience
by: Tse-Yi Li, et al.
Published: (2016)

Transcendent experience, process, and praxis within the 'Transcendence Movement'
by: Beasley, Keith
Published: (2013)

Successful olaparib desensitization using a novel one-day protocol
by: Rongbo Zhu, et al.
Published: (2020-11-01)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
by: Jonathan A. Ledermann, et al.
Published: (2019-05-01)

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
by: Baldwin P, et al.
Published: (2018-11-01)

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
by: Shaw HM, et al.
Published: (2013-09-01)